Skip to main
ACLX

Arcellx (ACLX) Stock Forecast & Price Target

Arcellx (ACLX) Analyst Ratings

Based on 14 analyst ratings
Hold
Strong Buy 14%
Buy 7%
Hold 79%
Sell 0%
Strong Sell 0%

Bulls say

Arcellx Inc. has positioned itself favorably in the biotechnology sector through its impactful collaboration with Gilead, which enhances its commercial prospects by leveraging KITE's cell therapy manufacturing and patient support capabilities. The clinical performance of Anito-cel, particularly its comparable durability to existing CAR-T therapies, alongside anticipated regulatory approvals by the end of 2026, underscores confidence in achieving substantial revenue growth, with peak sales estimates reaching up to $7 billion. This combination of strong clinical potential, strategic partnerships, and promising market opportunities suggests a positive outlook for the company's financial trajectory.

Bears say

The financial outlook for Arcellx Inc. is negatively impacted by significant risks including the potential failure to produce additional successful candidates from its therapy platforms and reliance on the completion of its acquisition by Gilead Sciences, which carries substantial uncertainties. The company’s valuation has been downgraded following the proposed acquisition, indicating concerns over its current and future revenue potential amidst competitive pressures and regulatory challenges. Furthermore, the financial projections incorporate risks related to potential dilution from further financing needs and the inherent uncertainties associated with clinical development, all contributing to a cautious stance on the stock.

Arcellx (ACLX) has been analyzed by 14 analysts, with a consensus rating of Hold. 14% of analysts recommend a Strong Buy, 7% recommend Buy, 79% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arcellx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arcellx (ACLX) Forecast

Analysts have given Arcellx (ACLX) a Hold based on their latest research and market trends.

According to 14 analysts, Arcellx (ACLX) has a Hold consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $115.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $115.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arcellx (ACLX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.